SCHEMBL6776958

SCHEMBL6776958

CCOC(=O)c1cn(C2CC2)c2c(F)c(N3CCNCC3)c(F)cc2c1=O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.59
ALDH1A1 P00352 6/20 0.51
KCNH2 Q12809 5/20 0.51
KDM4E B2RXH2 5/20 0.51
HPGD P15428 5/20 0.51
HSD17B10 Q99714 5/20 0.51
POLB P06746 2/20 0.51
OPRM1 P35372 2/20 0.51
PRKD3 O94806 1/20 0.51
ALOX15 P16050 1/20 0.51
CLK2 P49760 1/20 0.51
CLK4 Q9HAZ1 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
TOP2A P11388 2/20 0.50
TOP2B Q02880 2/20 0.50
LMNA P02545 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CHRM2 P08172 1/20 0.47
CHRM1 P11229 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10895468 0.92 ALDH1A1 (0.57) ADRB2ALDH1A1KCNH2KDM4EHPGD
SCHEMBL7131518 0.90 ADRB2 (0.59) ADRB2ALDH1A1KCNH2KDM4EHPGD
SCHEMBL6784057 0.89 KCNH2 (0.66) ADRB2ALDH1A1KCNH2KDM4EHPGD
SCHEMBL7131512 0.89 ADRB2 (0.59) ADRB2ALDH1A1KCNH2KDM4EHPGD
SCHEMBL6777872 0.89 KCNH2 (0.55) ADRB2ALDH1A1KCNH2KDM4EHPGD
SCHEMBL10913645 0.87 KCNH2 (0.46) ADRB2ALDH1A1KCNH2KDM4EHPGD
SCHEMBL9668175 0.87 ADRB2 (0.60) ADRB2ALDH1A1KCNH2KDM4EHPGD
SCHEMBL9735325 0.86 KCNH2 (0.57) ADRB2ALDH1A1KCNH2KDM4EHPGD
SCHEMBL29638251 0.86 ALDH1A1 (0.66) ALDH1A1KCNH2KDM4EHPGDHSD17B10
SCHEMBL8616936 0.86 ALDH1A1 (0.66) ALDH1A1KCNH2KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401829-B1 NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS MICROBIOTIX INC (US) 2012-08-22 EP disclosed
US-6777420-B2 A URACIL COMPOUNDS AS ENZYME INHIBITORS, INHIBIT BACTERIAL DNA POLYMERASE, TREATING BACTERIAL DISEASES MICROBIOTIX, INC. 2004-08-17 US disclosed
US-20030181719-A1 Novel heterocyclic antibacterial compounds MICROBIOTIX, INC. 2003-09-25 US disclosed
EP-0793656-B1 NOVEL BENZYL PYRIMIDINES BASILEA PHARMACEUTICA AG (CH) 2003-03-26 EP disclosed
US-5763450-A BACTERICIDES; TREATMENT OF INFECTIOUS DISEASES HOFFMANN-LA ROCHE INC. (US) 1998-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181719-A1 Novel heterocyclic antibacterial compounds TOP1, TOP2A, TOP2B ADRB2 4210/4885ALDH1A1 2897/4885KCNH2 2497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.